Peels for Active Acne

For active acne, the peel that earns its place is salicylic acid — and it earns it because of three properties that map directly onto acne pathophysiology: it is lipophilic (so it concentrates in the sebaceous follicle), comedolytic (so it loosens and clears the keratin-and-sebum plug), and anti-inflammatory (so it calms the papules and pustules already present). A salicylic peel is an adjunct to medical acne therapy, not a substitute for it. Used in the right patient — comedonal or mild-to-moderate inflammatory acne — it accelerates clearance and improves texture; used in the wrong patient — nodulocystic, scarring or rapidly progressive disease — it wastes time and can aggravate. Knowing which patient is in front of you is the whole lesson.

Why salicylic acid, specifically

Acne begins in the sebaceous follicle: follicular hyperkeratinisation forms the microcomedone, sebum accumulates, Cutibacterium acnes proliferates, and inflammation follows. A useful peeling agent has to reach that compartment. Salicylic acid does, because of its chemistry.

The other AHAs (glycolic, lactic) are water-soluble and act mainly at the surface; they are useful for tone and texture but do not target the follicle the way a lipophilic BHA does. That follicular targeting — plus salicylic acid's self-limiting depth — is why it is the default chemistry for an in-clinic acne peel, and the safest one to reach for in darker skin.

When peels help — and when they do not

The honest framing for a practising dermatologist is that a peel is one tool inside a medical acne plan, not the plan itself.

The pattern is consistent: peels add value where the disease is superficial and follicular and the goal is to clear plugs and calm low-grade inflammation. They add nothing — and lose you time — where the disease is deep, nodular or scarring, which needs systemic medical therapy. A peel never replaces a topical retinoid or an appropriate oral agent; it sits alongside them.

A practical safety note: peel active, intact skin, not excoriated or secondarily infected lesions. Pause peeling during a flare with open or weeping lesions, and never peel a patient on systemic isotretinoin or in the months around it without observing the usual healing-margin caution. In Fitzpatrick IV–VI, the inflammatory load of the acne itself is already generating PIH, so the peel must lower net inflammation, not add to it.

Fitting the peel into a real acne regimen

A salicylic peel works best as the in-clinic accelerator on top of a home regimen that is doing the daily work.

• Keep the topical retinoid running. The retinoid normalises follicular keratinisation between sessions; the peel clears what has already plugged. They are complementary, not redundant.
• Space sessions sensibly. Superficial salicylic peels are typically run as a short series at roughly fortnightly intervals, titrated to tolerance rather than to a fixed number.
• Watch the barrier. Acne patients are often already on drying topicals; stacking an aggressive peel on a compromised barrier provokes irritation and, in darker skin, PIH. Prime and moisturise.
• Protect from UV. Post-peel photoprotection is non-negotiable in IV–VI — unprotected sun in the post-peel window is the most reliable way to convert a treated papule into a dark mark.

Key takeaway

For active acne, reach for salicylic acid: it is lipophilic, comedolytic and anti-inflammatory, so it targets the sebaceous follicle where acne actually lives, and its self-limiting depth makes it the safest peel chemistry across Fitzpatrick IV–VI. Use it as an adjunct in comedonal and mild-to-moderate inflammatory acne, on top of — never instead of — medical therapy, and refer nodulocystic, scarring or rapidly progressive disease for systemic management. Keep the barrier intact, the retinoid running and the photoprotection strict, and the peel becomes a reliable accelerator rather than a source of new pigment.